To Compare the Efficacy and Safety of Using oXiris and M100 During CRRT

Launched by MOHD ZULFAKAR MAZLAN, MBBS · May 31, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two types of filters, called Oxiris and M100, to see which one works better and is safer for patients with pneumonia-related acute kidney injury (AKI). The study is looking at how well these filters can reduce a substance in the blood called IL-6, which is linked to inflammation, as well as other important blood measurements. Researchers also want to understand how these filters affect overall patient health, including the length of time spent in the hospital or on a ventilator, and whether they influence survival rates over 28 days.

To participate in this trial, individuals need to be adults over 18 years old who have been diagnosed with septic shock and severe kidney failure. Unfortunately, patients who are critically ill and expected to pass away soon, pregnant women, or those with certain bleeding disorders cannot take part. If eligible, participants can expect close monitoring during their treatment, and their experiences will contribute to understanding how to improve care for patients with similar health issues in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All adult patients aged\>18 years old
• • Diagnosis of septic shock
• • Diagnosis of KDIGO stage 3 acute renal failure
• Exclusion Criteria:
• • Moribund patient or patient that is expected to die within 72 hours
• • Pregnancy
• • patient with a bleeding tendency or known allergy to heparin